Silly jet', you're still debating the clinical studies, which led to $AEGR US & Europe approval, but no $ISIS approval overseas. The FDA even said 'in-spite of the increased risks with the $ISIS drug Kynamro, we are glad to offer more choice for HoFH patients in the States', after the EMA said "NO" to $ISIS and Kynamro in Europe. And now you're quoting snake oil salesman Cramer? He's had $ISIS egg on his face since he told his sheep to buy ISIS at its high and then it plunged 40%. Simply put: I too am glad HoFH patients have an educated choice to make here in the States, and they continue to pick AEGR's Juxtapid.
I say invest away to your heart's content. We'll see how things go over the next year. There are so many other biotechs with real platforms, and honest management in the 40 dollar price range, SGEN for example, that this one drug dog with a 20 year pill is a really bad investment. t
Great call on $SGEN ...if it was April 2013. SGEN has a $5.1B+ market cap now with 123M+ shares to divide the earnings. $AEGR is at a market cap of $1.2B with only 29.4M shares. I'm glad to hear you changing your tone about AEGR though (today of all days, when the Phase 3 study in Japan is announced) and you're now only harping about the opportunity costs involved (meaning you're backing away from your other diatribes).